PF-Atlas › Clinical Trials › NCT05576324

Effect of the CFTR-modulating Triple Therapy Elexacaftor - Tezacaftor - Ivacaftor

Elexacaftor / Ivacaftor / Tezacaftor · Not specified

Registry ID
NCT05576324
Phase
Not specified
Status
Unknown
Drug / intervention
Elexacaftor / Ivacaftor / Tezacaftor
Sponsor
University of Erlangen-Nürnberg Medical School
Start
2020-12-30
Enrollment
130
Locations
1

About this trial

The aim of this study is to investigate the frequency distribution, cytokine profile and function of peripheral, mononuclear leukocyte populations (monocytes, NK cells, T/B lymphocytes) and their correlation to clinical and biochemical parameters in patients with cystic fibrosis receiving CFTR modulatory triple therapy consisting of elexacaftor, tezacaftor and ivacaftor and to compare it with patients without CFTR modulatory therapy and healthy control subjects.

View NCT05576324 on ClinicalTrials.gov →

Explore related

All Elexacaftor / Ivacaftor / Tezacaftor trialsAll IPF trials

Related trials

Elexacaftor / Ivacaftor / Tezacaftor — NCT07148739Elexacaftor / Ivacaftor / Tezacaftor — NCT05699148
Medical disclaimer. This page summarizes public trial data for NCT05576324 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.